A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

• Joseph Mikhael,
• Karim Belhadj-Merzoug,
• Cyrille Hulin,
• Laure Vincent,
• Philippe Moreau,
• Cristina Gasparetto,
• Ludek Pour,
• Ivan Spicka,
• Ravi Vij,
• Jeffrey Zonder,
• Djordje Atanackovic,
• Nashat Gabrail,
• Thomas G. Martin,
• Aurore Perrot,
• Samira Bensfia,
• Qilong Weng,
• Claire Brillac,
• Dorothée Semiond,
• Sandrine Macé,
• Kathryn P. Corzo,
• Xavier Leleu

Affiliations

Joseph Mikhael

Translational Genomics Research Institute, City of Hope Cancer Center

Karim Belhadj-Merzoug

Unité Hémopathies Lymphoïdes, CHU Henri Mondor

Cyrille Hulin

Service d’hématologie, CHRU Hôpitaux de Brabois

Laure Vincent

Département d’hématologie Clinique, Centre Hospitalier Universitaire de Montpellier

Philippe Moreau

Hematology Department, Nantes University Hospital

Cristina Gasparetto

Duke Cancer Institute, Duke University

Ludek Pour

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno

Ivan Spicka

1st Department of Medicine—Department of Hematology First Faculty of Medicine Charles University and General Hospital in Prague

Ravi Vij

Division of Medical Oncology, Washington University

Jeffrey Zonder

Department of Oncology, Karmanos Cancer Institute, Wayne State University

Djordje Atanackovic

Department of Medicine, Bone Marrow Transplant, University of Maryland Greenebaum Cancer Center

Nashat Gabrail

Gabrail Cancer Center

Thomas G. Martin

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco

Aurore Perrot

CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’hématologie

Samira Bensfia

Sanofi Global Oncology

Qilong Weng

Sanofi Clinical Sciences and Operations

Claire Brillac

Sanofi Translational Medicine and Early Development

Dorothée Semiond

Sanofi Translational Medicine and Early Development

Sandrine Macé

Sanofi Translational Medicine and Early Development

Kathryn P. Corzo

Sanofi Global Oncology

Xavier Leleu

Takeda Pharmaceuticals